Angiogenesis最新文献

{"title":"Acute aortic dissection in a patient with Hereditary Hemorrhagic Telangiectasia associated with Juvenile Polyposis due to SMAD4 mutation: case report and literature review","authors":"Catalina Pezzoto,&nbsp;Ana Braslavsky,&nbsp;Carolina Vázquez,&nbsp;Candelaria Serrano,&nbsp;Marcelo Serra","doi":"10.1007/s10456-025-09981-9","DOIUrl":"10.1007/s10456-025-09981-9","url":null,"abstract":"<div><h3>Objective</h3><p>We present a novel case of concurrent Hereditary Hemorrhagic Telangiectasia-Juvenile Polyposis Syndrome (HHT-JP), resulting in a fatal aortic dissection. Given rarity of the case, we aimed to perform a comprehensive review of the existing literature to better characterize this clinical complication in this population.</p><h3>Methods</h3><p>We conducted a literature review on HHT-JP syndrome using PubMed, focusing on English-language articles published between 2010 and 2024, specifically case reports and small series. Search terms \"Hereditary Hemorrhagic Telangiectasia\", “Osler-Weber-Rendu syndrome” and \"Juvenile Polyposis\" were used. Exclusion criteria included population studies lacking detailed individual characteristics related to Hereditary Hemorrhagic Telangiectasia (HHT) or Juvenile Polyposis (JP). Duplicate articles were removed, and data were extracted on patient demographics, clinical presentations, diagnostic criteria (Curaçao criteria for HHT, Jass criteria for JP), treatments, and outcomes.</p><h3>Results</h3><p>Fifty-six individuals with the MADH4 mutation met the inclusion criteria and were compared to our patient. The age range of the total cohort of fifty-six participants spanned from 6 to 66 years, with a distribution between men and women. The typical clinical presentation of HHT-JP was observed in most cases. Notably, only one patient from previous literature exhibited aortic dissection, aligning with our patient's presentation. Additionally, three other patients had aortic aneurysms. Musculoskeletal and other cardiovascular anomalies were also identified and described.</p><h3>Discussion</h3><p>While aortic aneurysms prevail in HHT-JP syndrome, aortic dissection cases are extremely rare. This case highlights the need for vigilant screening to identify aortic anomalies in this specific patient subset, emphasizing the severe complications associated with this syndrome combination.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 3","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SDF-1α mRNA therapy in peripheral artery disease","authors":"Tinghong Zhang,&nbsp;Binqiang Zhu,&nbsp;Shijie Deng,&nbsp;Jinling Qin,&nbsp;Jingyuan Zhang,&nbsp;Shu Meng","doi":"10.1007/s10456-025-09979-3","DOIUrl":"10.1007/s10456-025-09979-3","url":null,"abstract":"<div><p>Stromal cell-derived factor-1 alpha (SDF-1α) is a promising target for therapeutic angiogenesis in ischemic diseases such as peripheral artery disease (PAD). However, the clinical application of SDF-1α protein or plasmid-based gene therapy is unsuccessful. mRNA therapy has shown great promise in protein replacement. Here, we developed DOPE-lipid nanoparticles (LNPs) encapsulating SDF-1α mRNA (LNP@SDF-1α) for efficient gene delivery. In vitro, LNP@SDF-1α treatment of human umbilical vein endothelial cells (HUVECs) significantly enhanced endothelial migration, tube formation, and increased monocyte adhesion, demonstrating robust pro-angiogenic activity. In vivo, LNP@SDF-1α transfected HUVECs showed enhanced angiogenic capacity in a murine Matrigel plug model. Furthermore, in a mouse hindlimb ischemia model, intramuscular injection of LNP@SDF-1α into ischemic limbs accelerated blood flow recovery, as assessed by laser speckle contrast imaging. Immunofluorescence staining revealed a marked increase in capillary and arteriole densities in treated tissues. Angiogenic protein profiling demonstrated an upregulation of pro-angiogenic factors, including VEGF and Ang-1, and a downregulation of anti-angiogenic factors. No significant toxicity was observed in major organs, indicating the safety of this approach. Our study demonstrates that SDF-1α mRNA therapy, delivered via DOPE-LNPs, significantly promotes vascular regeneration in ischemic tissues by enhancing angiogenesis and arteriogenesis, thereby restoring blood perfusion. This approach presents a promising therapeutic option for PAD and suggests broader applications of mRNA-based therapies for ischemic diseases.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 3","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-025-09979-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The VEGF decoy receptor soluble Fms-like tyrosine kinase 1 binds to macrophages","authors":"Cleo C. L. van Aanhold,&nbsp;Qing Yong,&nbsp;Lisa Landman,&nbsp;Samiksha Sardana,&nbsp;Anouk B. Bouwmeester,&nbsp;Kyra L. Dijkstra,&nbsp;Ron Wolterbeek,&nbsp;Hailiang Mei,&nbsp;Rayman T. N. Tjokrodirijo,&nbsp;Arnoud H. de Ru,&nbsp;Peter A. van Veelen,&nbsp;Jan A. Bruijn,&nbsp;Cees van Kooten,&nbsp;Hans J. Baelde","doi":"10.1007/s10456-025-09980-w","DOIUrl":"10.1007/s10456-025-09980-w","url":null,"abstract":"<div><h3>Background</h3><p>Soluble Fms-like Tyrosine kinase-1 (sFLT1) is a native inhibitor of VEGF, best known for its antiangiogenic effects in preeclampsia. sFLT1 also reduces chronic inflammation and promotes tissue repair. In experimental diabetic nephropathy, we previously found that sFLT1 ameliorates kidney fibrosis and reduces the infiltration of macrophages. How sFLT1 regulates inflammation is still incompletely understood. Based on the direct association of sFLT1 with various cell types, we here studied whether sFLT1 interacts with macrophages to modulate inflammation.</p><h3>Methods</h3><p>Using various macrophage cell lines, sFLT1 cell surface binding was detected with flow cytometry. Enzyme studies, mass spectrometry and RNAseq were employed to identify potential sFLT1 cell surface interactors and effects of sFLT1 on macrophage signaling.</p><h3>Results</h3><p>Soluble FLT1 binds to primary macrophages, THP-1 and RAW264.7 macrophages in vitro. Alternative activation with IL-4 increases sFLT1 binding in THP-1 macrophages, whereas proinflammatory activation with IFN-γ and LPS decreases binding. Binding of sFLT1 depends on heparan sulphates, and colocalizes with the membrane heparin sulfate proteoglycan neuropilin-1. Incubation with sFLT1 reduces the gene expression of chemokine receptors.</p><h3>Conclusion</h3><p>Our results show that sFLT1, while typically associated with angiogenesis, also directly interacts with macrophages. Alternative activation of macrophages by IL-4 strongly increases binding of sFLT1 to the cell surface membrane, possibly via the VEGF co-receptor neuropilin-1. Considering sFLT1’s anti-inflammatory effects in animal studies, our findings indicate a novel function for sFLT1 to directly control anti-inflammatory macrophage function. </p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 3","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-025-09980-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed lineage kinase (MLK) controls tumor development and angiogenesis","authors":"Shashi Kant,&nbsp;Amada D. Caliz,&nbsp;Hyung-Jin Yoo,&nbsp;Gaganpreet Kaur,&nbsp;Heather Learnard,&nbsp;Hassan A. Khalil,&nbsp;Roger J. Davis,&nbsp;John F. Jr. Keaney","doi":"10.1007/s10456-025-09978-4","DOIUrl":"10.1007/s10456-025-09978-4","url":null,"abstract":"<div><p>Cancer is among the leading causes of death in the USA and worldwide. Solid tumors require the formation of new blood vessels (angiogenesis) for their growth. The endothelium plays a crucial role in angiogenesis and tumor progression. Hypoxic stress generated by tumors can activate stress kinases such as mixed lineage kinases (MLKs). Publicly available datasets on lung adenocarcinoma, along with our experimental findings, indicate that MLK2 and MLK3 are expressed in human lung tumors. In this study, using three distinct mouse models of tumor development, we demonstrated that MLK2 (<i>MAP3K10</i>) and MLK3 (<i>MAP3K11</i>) are essential for tumor growth and angiogenesis. Furthermore, MLK2 and MLK3 are highly expressed in the endothelium and are necessary for endothelial proliferation, migration, and angiogenesis. In the endothelium, MLKs regulate the expression of angiogenic growth factors and metalloproteinases, including <i>Pgf</i>,<i> Vegfa</i>,<i> Angptl4</i>,<i> Adam8</i>,<i> and Mmp9</i>. Additionally, the MLK family of kinases acts through the long noncoding RNA (lncRNA) <i>H19</i> to control the expression of these pro-angiogenic factors in the endothelium. Collectively, these findings suggest that the MLK-H19 axis coordinates endothelial function, angiogenesis, and tumor growth.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 3","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"G protein-coupled receptor GPR182 negatively regulates sprouting angiogenesis via modulating CXCL12-CXCR4 axis signaling","authors":"Changsheng Chen,&nbsp;Wei Liu,&nbsp;Fang Yuan,&nbsp;Xiaoning Wang,&nbsp;Xi Xu,&nbsp;Chang Chun Ling,&nbsp;Xiaojuan Ge,&nbsp;Xiaozhong Shen,&nbsp;Bowen Li,&nbsp;Yuqian Shen,&nbsp;Dong Liu","doi":"10.1007/s10456-025-09977-5","DOIUrl":"10.1007/s10456-025-09977-5","url":null,"abstract":"<div><p>Angiogenesis is a critical process for tumor progression, regulated by various signaling pathways. Although antiangiogenic therapies targeting the VEGF pathway have shown potential, their effectiveness is inconsistent across different tumor types. GPR182, an endothelial cell-specific G protein-coupled receptor, is frequently downregulated in hypervascular tumors, but its specific role in angiogenesis has not been well defined. Our study reveals that GPR182 expression is markedly reduced in hepatocellular carcinoma (HCC) and inversely correlates with CD31, a pan-endothelial marker. In zebrafish embryos, Gpr182 deficiency resulted in enhanced angiogenic sprouting and hypervascularization, and GPR182-deficient human umbilical vein endothelial cells (HUVECs) showed increased migration and proliferation. At the molecular level, GPR182 acts as a decoy receptor, binding CXCL12 and regulating its gradient, which in turn suppresses CXCR4-mediated angiogenesis. The pharmacological blockade of CXCR4 with AMD3100 corrected the abnormal angiogenic phenotype in Gpr182-deficient zebrafish embryos and in the livers of a zebrafish HCC model. This work uncovers GPR182 as a negative regulator of angiogenesis, a key process in tumor growth and metastasis, and proposes that targeting GPR182 may offer a novel therapeutic approach for antiangiogenic strategies in cancer treatment.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 3","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-025-09977-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leakage","authors":"Bongnam Jung,&nbsp;Hitomi Yagi,&nbsp;Andrew Kuo,&nbsp;Tim F. Dorweiler,&nbsp;Masanori Aikawa,&nbsp;Taku Kasai,&nbsp;Sasha A. Singh,&nbsp;Andrew J. Dannenberg,&nbsp;Zhongjie Fu,&nbsp;Colin Niaudet,&nbsp;Lois E. H. Smith,&nbsp;Timothy Hla","doi":"10.1007/s10456-025-09975-7","DOIUrl":"10.1007/s10456-025-09975-7","url":null,"abstract":"<div><p>Neovascular age-related macular degeneration (nAMD) is a major cause of vision loss worldwide. Current standard of care is repetitive intraocular injections of vascular endothelial growth factor (VEGF) inhibitors, although responses may be partial and non-durable. We report that circulating sphingosine 1-phosphate (S1P) carried by apolipoprotein M (ApoM) acts through the endothelial S1P receptor 1 (S1PR1) to suppress choroidal neovascularization (CNV) in mouse laser-induced CNV, modeling nAMD. In humans, low plasma ApoM levels were associated with increased choroidal and retinal pathology. Additionally, endothelial <i>S1pr1</i> knockout and overexpressing transgenic mice showed increased and reduced CNV lesion size, respectively. Systemic administration of ApoM-Fc, an engineered S1P chaperone protein, not only attenuated CNV to an equivalent degree as anti-VEGF antibody treatment but also suppressed pathological vascular leakage. We suggest that modulating circulating ApoM-bound S1P action on endothelial S1PR1 provides a novel therapeutic strategy to treat nAMD.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 2","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-025-09975-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143861313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial USP11 drives VEGFR2 signaling and angiogenesis via PRDX2/c-MYC axis","authors":"Can Chen,&nbsp;Zilong Chen,&nbsp;Ruijie Luo,&nbsp;Wanheng Tu,&nbsp;Minwen Long,&nbsp;Minglu Liang,&nbsp;Min Cheng,&nbsp;Zhaohui Wang,&nbsp;Kai Huang,&nbsp;Cheng Wang","doi":"10.1007/s10456-025-09976-6","DOIUrl":"10.1007/s10456-025-09976-6","url":null,"abstract":"<div><p>Angiogenesis is a crucial component of various physiological and pathological processes, including embryonic development, ischemic diseases, and tumor progression. Recent studies have highlighted the importance of ubiquitinases in angiogenesis. In this study, we utilized RNA sequencing data of the mouse retinal development model from the GEO database to identify the potential proangiogenic deubiquitinases and found USP11 was significantly upregulated. Although USP11 is known to regulate cell survival, DNA repair, and oxidative stress in cancers and ischemic conditions, its direct role in endothelial angiogenesis remains poorly understood. Here, we demonstrated that USP11 expression correlates with key pro-angiogenic genes and is significantly upregulated at both mRNA and protein levels in VEGF-treated human umbilical vein endothelial cells (HUVECs). USP11 knockout markedly inhibited angiogenesis both in vivo and in vitro, whereas USP11 overexpression promoted angiogenesis. Mechanistically, USP11 binds to PRDX2, facilitating the removal of its K63-linked polyubiquitination, which promotes its translocation into the nucleus. This facilitates the concurrent nuclear translocation of c-MYC, a PRDX2 interactor, which subsequently enhances the transcription of <i>KDR</i> (encoding VEGFR2) and activates the VEGFR2 signaling pathway. Our findings suggest that USP11 promotes angiogenesis by upregulating VEGFR2 expression through the PRDX2/c-MYC pathway, indicating that USP11 could serve as a potential target for clinical interventions in angiogenesis-related diseases.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 2","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143801226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvascular and cerebrovascular alterations in Raynaud’s phenomenon and fibromyalgia","authors":"Angelo Nigro","doi":"10.1007/s10456-025-09974-8","DOIUrl":"10.1007/s10456-025-09974-8","url":null,"abstract":"","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 2","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial transcriptomic, epigenomic and proteomic data challenge the proposed role for TSAd in vascular permeability","authors":"James T. Brash,&nbsp;Guillermo Diez-Pinel,&nbsp;Luca Rinaldi,&nbsp;Raphael F. P. Castellan,&nbsp;Alessandro Fantin,&nbsp;Christiana Ruhrberg","doi":"10.1007/s10456-025-09971-x","DOIUrl":"10.1007/s10456-025-09971-x","url":null,"abstract":"<div><p>The vascular endothelial growth factor VEGF drives excessive vascular permeability to cause tissue-damaging oedema in neovascular and inflammatory diseases across multiple organs. Several molecular pathways have been implicated in VEGF-induced hyperpermeability, including binding of the VEGF-activated tyrosine kinase receptor VEGFR2 by the T-cell specific adaptor (TSAd) to recruit a SRC family kinase to induce junction opening between vascular endothelial cells (ECs). Inconsistent with a universal role for TSAd in permeability signalling, immunostaining approaches previously reported TSAd only in dermal and kidney vasculature. To address this discrepancy, we have mined publicly available omics data for expression of TSAd and other permeability-relevant signal transducers in multiple organs affected by VEGF-induced vascular permeability. Unexpectedly, TSAd transcripts were largely absent from EC single cell RNAseq data, whereas transcripts for other permeability-relevant signal transducers were detected readily. TSAd transcripts were also lacking from half of the EC bulk RNAseq datasets examined, and in the remaining datasets appeared at low levels concordant with models of leaky transcription. Epigenomic EC data located the TSAd promoter to closed chromatin in ECs, and mass spectrometry-derived EC proteomes typically lacked TSAd. By suggesting that TSAd is not actively expressed in ECs, our findings imply that TSAd is likely not critical for linking VEGFR2 to downstream signal transducers for EC junction opening.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 2","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-025-09971-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143612228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-privileged cord blood-derived endothelial colony-forming cells: advancing immunomodulation and vascular regeneration","authors":"David M. Smadja,&nbsp;Yanis Berkane,&nbsp;Nun K. Bentounes,&nbsp;Jeanne Rancic,&nbsp;Audrey Cras,&nbsp;Cécile Pinault,&nbsp;Marie Ouarne,&nbsp;Elise Paucod,&nbsp;Walid Rachidi,&nbsp;Alexandre G. Lellouch,&nbsp;Maxime Jeljeli","doi":"10.1007/s10456-025-09973-9","DOIUrl":"10.1007/s10456-025-09973-9","url":null,"abstract":"<div><p>Cord blood-derived endothelial colony-forming cells (CB-ECFCs) hold significant promise for regenerative medicine due to their unique vasculogenic and immunomodulatory properties. These cells exhibit a superior proliferative capacity, robust ability to form vascular networks, and lower immunogenicity compared to adult and embryonic stem cell-derived counterparts. The immune-privileged characteristics of CB-ECFCs, including reduced expression of pro-inflammatory mediators and tolerance-inducing molecules such as HLA-G, further enhance their therapeutic potential. Their low immunogenicity minimizes the risk of immune rejection, making them suitable for allogenic cell therapies. Their application extends to complex tissue engineering and organ revascularization, where their ability to integrate into three-dimensional scaffolds and support vascular tree formation represents a significant advancement. Moreover, CB-ECFCs’ capability to adapt to inflammatory stimuli and retain immunological memory highlights their functional versatility in dynamic microenvironments. This review highlights the remarkable ontogeny of ECFCs while unveiling the unparalleled potential of CB-ECFCs in revolutionizing regenerative medicine. From pre-vascularizing engineered tissues and organoids to pioneering cell-based therapies for cardiovascular, dermatological, and degenerative diseases, CB-ECFCs stand at the forefront of cutting-edge biomedical advancements, offering unprecedented opportunities for therapeutic innovation. By leveraging their vasculogenic, immune-regulatory, and regenerative capacities, CB-ECFCs offer a robust alternative for addressing the challenges of vascular repair and organ engineering. Future research should focus on unraveling their transcriptomic and functional profiles to optimize clinical applications and advance the field of regenerative medicine.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"28 2","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-025-09973-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}